NEW YORK (Reuters Health), Nov 13 - The incidence of needle track seeding following biopsy of suspected hepatocellular cancer (HCC) appears to be 2.7%, according to findings of a meta-analysis by U.K. researchers published in the November issue of Gut.
Dr. Darius Mirza of University Hospital Birmingham NHS Trust and colleagues note that needle biopsy in such circumstances might be informative, but it is not generally recommended because of the risk of seeding. However, the incidence is ill defined.
To investigate further, the researchers reviewed the literature and identified seven retrospective studies and one prospective observational study that reported on needle track seeding in a total of 1,340 patients.
The team calculated that the incidence of HCC overall was 2.7%, or 0.9% per year. There is some uncertainty, they add, but the highest rates with which the data from the studies are compatible would be 4.0% overall or 1.3% per year.
In none of these reported cases of seeding was patient survival affected, and the lesion was successfully treated by resection and local ablation.
"Percutaneous image-guided biopsies of liver lesions should not be performed indiscriminately." Mirza told Reuters Health. "Nevertheless, there is a place for such a guided biopsy, but its use should be restricted to specialized liver transplant centers on a case-by-case basis, following multidisciplinary review."
Gut 2008;57:1592-1596.
Last Updated: 2008-11-11 17:06:22 -0400 (Reuters Health)
Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
